В статье описываются клинические рекомендации по диагностике и лечению волчаночного нефрита
Автор (ы): Захарова Е.В.
Журнал: НЕФРОЛОГИЯ И ДИАЛИЗ
Идентификаторы и классификаторы
Для цитирования:
ЗАХАРОВА Е.В. ПРОЕКТ ИНИЦИАТИВНЫХ КЛИНИЧЕСКИХ РЕКОМЕНДАЦИЙ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ ВОЛЧАНОЧНОГО НЕФРИТА // НЕФРОЛОГИЯ И ДИАЛИЗ. 2024. № S2, ТОМ 26
Текстовый фрагмент статьи
Системная красная волчанка (СКВ) – аутоиммунное заболевание неизвестной этиологии с широким спектром клинических проявлений, ассоциированных с образованием множества аутоантител к компонентам клеточного ядра и цитоплазмы, образованием и отложением иммунных комплексов и другими иммунными процессами [1, 2].
Список литературы
- Rahman A, Isenberg DA. Systemic lupus erythematosus. Nngl J Med. 2008;358(9):929-939. DOI: 10.1056/NEJMra071297
- Tsokos G.C. Systemic lupus erythematosus. N Engl J Med. 2011. 365(22):2110-2121. doi: 10.1056/NEJMra1100359
- Weening JJ, D’Agati VD, Schwartz MM et al. The classifi cation of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65(2):521-530. DOI: 10.1111/j.1523- 1755.2004.00443.x
- Rovin BH, Caster DJ, Cattran DC et al. Management and treatment of glomerular diseases (part 2): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies
Conference Kidney Int. 2019;95(2):281-295. DOI: 10.1016/j. kint.2018.11.008 - Rekvig OP, van der Vlag J. The pathogenesis and diagnosis of systemic lupus erythematosus: still not resolved. Semin Immunopathol. 2014;36:301-311. DOI: 10.1007/s00281-014-0428-6
- Mohan C, Putterman C. Genetics and pathogenesis of systemic lupus erythematosus and lupus nephritis. Nat Rev Nephrol. 2015;11(6):329-341. DOI: 10.1038/nrneph.2015.33
- Attar SM, Koshak EA. Medical conditions associated with a positive anti-double-stranded deoxyribonucleic acid. Saudi Med J. 2010;31(7):781-787.
- Sengupta M, Morel L. Lupus at the molecular level. Protein Cell. 2011;2(12):941-943. DOI: 10.1007/s13238-011-1123-1
- Danchenko N, Satia JA, Anthony MS . Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15(5):308-318. DOI: 10.1191/0961203306lu2305xx
- Aringer M, Costenbader K, Daikh D et al. 2019 European League Against Rheumatism/American College of Rheumatology Classifi cation Criteria for Systemic Lupus Erythematosus. Arthritis Rheum. 2019;71(9):1400-1412. DOI: 10.1002/art.40930
- Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI: a disease activity index for lupus patients. Arthritis Rheum. 1992;35(6):630-640. DOI: 10.1002/art.1780350606
- Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-291.
- Petri M, Kim MY, Kalunian KC et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl
- Bajema IM, Wilhelmus S, Alpers CE et al. Revision of the International Society of Nephrology/Renal Pathology Society classifi cation for lupus nephritis: clarifi cation of defi nitions, and modifi ed National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93(4):789-796. DOI: 10.1016/j. kint.2017.11.023
- Petri M, Orbai AM, Alarcon GS et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classifi cation criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. DOI: 10.1002/art.34473
- Bertsias GK, Pamfi l C, Fanouriakis A, Boumpas DT. Diagnostic criteria for systemic lupus erythematosus: has the time come? Nat Rev Rheumatol. 2013;9(11):687-694. DOI: 10.1038/ nrrheum.2013.103
- Almaani S, Meara A, Rovin BH. Update on Lupus Nephritis. Clin J Am Soc Nephrol. 2017;12(5):825-835. DOI: 10.2215/CJN.05780616.
- Schwartz MM, Korbet SM, Lewis EJ et al. The prognosis and pathogenesis of severe lupus glomerulonephritis. Nephrol Dial Transplant. 2008;23(4):1298-1306. DOI: 10.1093/ndt/gfm775
- Haring CM, Rietveld A, van den Brand JA et al. Segmental and global subclasses of class IV lupus nephritis have similar renal outcomes. J Am Soc Nephrol. 2012;23(1):149-154. DOI: 10.1681/ASN.2011060558
- Dube GK, Markowitz GS, Radhakrishnan J et al. Minimal change disease in systemic lupus erythematosus. Clin Nephrol. 2002;57(2):120-126. DOI: 10.5414/cnp57120
- Kraft SW, Schwartz MM, Korbet SM, Lewis EJ. Glomerular podocytopathy in patients with systemic lupus erythematosus. J Am Soc Nephrol. 2005;16(1):175-179. DOI: 10.1681/ ASN.2004050350
- Hernandez-Molina G, Garcia-Trejo LP, Uribe N et al. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp
Rheumatol. 2015;33(4):503-508. - Wu LH, Yu F, Tan Y et al. Inclusion of renal vascular lesions in the 2003 ISN/RPS system for classifying lupus nephritis improves renal outcome predictions. Kidney Int. 2013;83(4):715- 723. DOI: 10.1038/ki.2012.409
- Хроническая болезнь почек (ХБП). Клинические рекомендации. https://rusnephrology.org/wp-content/uploads/ 2020/12/CKD_final.pdf. [Chronic Kidney Disease (CKD). Clinical Recommendations. https://rusnephrology.org/ wp-content/uploads/2020/12/CKD_fi nal.pdf.] (In Russian)
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., Suppl. 2013;3:1-150. DOI: 10.1038/kisup.2012.73
- Камышова ЕС. Клинические практические лечению Хронической болезни почек (перевод на русский язык под ред. Е.В. Захаровой). Нефрология и диализ. 2017;19(1):23- 206.
Kamyshova ES. KDIGO 2012 Clinicheskie practicheskie recomendatsii po diagnostike i lecheniyu chroniceskoy bolesni pochek (Translation into Russian, ed by EV Zakharova). Nephrology and Dialysis. 2017;19(1):23-206. (In Russian) - Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int. 2024;105(4S):S117-S314. DOI: 10.1016/j. kint.2023.10.018
- Mosca M, Costenbader KH, Johnson SR et al. How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development of new classifi cation criteria. Arthritis Rheumatol. 2019;71(1):91-98. DOI: 10.1002/art.40674
- Leuchten N, Milke B, Winkler-Rohlfi ng B et al. Early symptoms of systemic lupus erythematosus (SLE) re-called by 339 SLE patients. Lupus. 2018;27(9):1431-1436. DOI: 10.1177/0961203318776093
- Козловская Н.Л., Захарова Е.В. Системная красная волчанка в книге Нефрология. Национальное руководство, краткое издание. Издательство «ГЭОТАР-Медиа». 2014. С.269-287. Kozlovskaya NL, Zakharova EV. Systemnaya krasnaya volchanka v knige Nefrologia. Natsionalnoe rukovodstvo, kratkoe izdanie. Publisher “GEOTAR-Media” 2014. P.269-287 ISBN: 987-5-9704-3014-9 (In Russian)
- Barbhaiya M, Zuily S, Naden R et al. 2023 ACR/EULAR antiphospholipid syndrome classifi cation criteria. Ann Rheum Dis. 2023;82(10):1258-1270. DOI: 10.1136/ard-2023-224609
- Balow JE. Clinical presentation and monitoring of lupus nephritis. Lupus. 2005;14(1):25-30. DOI: 10.1191/0961203305lu2055oa
- Corapi KM, Dooley MA, Pendergraft WF 3rd. Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther. 2015;17(1):110. DOI: 10.1186/s13075-015-0621-6
- Dall’Era M, Cisternas MG, Smilek DE et al. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Arthritis Rheumatol. 2015;67(5):1305-1313. DOI: 10.1002/art.39026
- Ugolini-Lopes MR, Seguro LPC, Castro MXF et al. Early proteinuria response: a valid real-life situation predictor of longterm lupus renal outcome in an ethnically diverse group with severe
biopsy-proven nephritis? Lupus Sci Med. 2017;4(1):e000213. DOI: 10.1136/lupus-2017-000213 - Tamirou F, Lauwerys BR, Dall’Era M et al. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the
MAINTAIN Nephritis Trial. Lupus Sci Med. 2015;2(1):e000123. DOI: 10.1136/lupus-2015-000123. - Wang S, Spielman A, Ginsberg M et al. Short- and Long- Term Progression of Kidney Involvement in Systemic Lupus Erythematosus Patients with Low-Grade Proteinuria. Clin J Am Soc Nephrol. 2022;17(8):1150-1158. DOI: 10.2215/CJN.01280122
- Konieczny A, Kasenberg I, Mikołajczak A et al. Baseline Proteinuria and Serum Creatinine Concentration as Clinical Predictors of Complete Renal Response in Patients with Lupus Nephritis: A Single-Center Experience. Int J of Environ Res Public Health. 2022;19(23):15909. DOI: 10.3390/ijerph192315909
- Sayer J, McCarthy MP, Schmidt JD. Identifi cation and signifi cance of dysmorphic versus isomorphic hematuria. J Urol. 1990;143(3):545-548. DOI: 10.1016/s0022-5347(17)40015-2
- Rahman P, Gladman DD, Ibanez D et al. Significance of isolated hematuria and isolated pyuria in systemic lupus erythematosus. Lupus. 2001;10(6):418-423. DOI: 10.1191/096120301678646164
- Ding JYC, Ibanez D, Gladman D, Urowitz MB. Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity. J Rheumatol. 2015;42(3):437-440. DOI: 10.3899/jrheum.140415
- Korbet SM, Whittier WL, Lewis EJ. The Impact of Baseline Serum Creatinine on Complete Remission Rate and Long- Term Outcome in Patients with Severe Lupus Nephritis. Nephron Extra. 2016;6(2):12-21. DOI: 10.1159/000448487
- Almaani S, Bhatt U, Arriens C. Creatinine Fluctuation in Patients with Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney Int Rep. 2020;5(8):1302-1305. DOI:10.1016/j.
ekir.2020.05.011 - Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney
Int. 2021;100(4S):S1-S276. DOI: 10.1016/j.kint.2021.05.021 - Бобкова ИН, Буланов НМ, Захарова ЕВ и соавт. Клинические практические рекомендации KDIGO 2021 под ред. Е.В. Захаровой). Нефрология и диализ.
2022;24(4):577-874. Bobkova IN, Bulanov NM, Zakharova EV et al. KDIGO 2021 Clinicheskie practicheskie recomendatsii po lecheniyu glomeruljarnykh bolesney (Translation into Russian ed by EV Zakharova). Nephrology and Dialysis. 2022;24(4):577-874. (In Russian). DOI: 10.28996/2618-9801-2022-4-577-874 - Kidney Disease: Improving Global Outcomes (KDIGO) Lupus Nephritis Work Group. KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis. Kidney Int.
2024;105(1S):S1-S69. DOI: 10.1016/j.kint.2023.09.002 - Gladman DD, Ibañez D, Ruiz I, Urowitz MB. Recommendations for frequency of visits to monitor systemic lupus erythematosus in asymptomatic patients: data from an observational
cohort study. J Rheumatol. 2013;40(5):630-633. DOI: 10.3899/ jrheum.121094 - Bertsias GK, Tektonidou M, Amoura Z et al. Joint European League Against Rheumatism and European Renal Association- European Dialysis and Transplant Association (EULAR/
ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771- 1782. DOI: 10.1136/annrheumdis-2012-201940 - Захарова ЕВ. Совместные рекомендации Европейской лиги по борьбе с ревматизмом и Европейской почечной ассоциации-Европейской ассоциации диализа и трансплантации по ведению волчаночного нефрита у взрослых и детей (перевод на русский язык). Нефрология и диализ. 2012;14(4):206-222. Zakharova EV. Sovmestnye recomendatsii Evropeyskoy ligi po borbe s revmatismom y Evropeyskoy pochechnoy assaciacii- Evropeyskot associacii dyalisa y transplantacii po vedeniyu volchanochnogo nefrita u vsroslyh y detey (Translation into Russian). Nephrology and Dialysis. 2012;14(4):206-222. (In Russian)
- Козловская НЛ, Моисеев СВ, Новиков ПИ. Лечение волчаночного нефрита: новые рекомендации EULAR/ERAEDTA. Клиническая фармакология и терапия. 2013;22(1):62-
- Kozlovskaya NL, Moiseev SV, Novikov PI. Lechenie volchanochnogo nefrita: novie recomendatsii EULAR/ERA-EDTA. Kliniceskaya pharmakologia y terapia. 2013;22(1):62-68. (In Russian)
- Козловская НЛ, Захарова ЕВ, Коротчаева ЮВ. Гломерулонефрит при системной красной волчанке в книге Национальные клинические рекомендации по лечению гломерулонефритов. Издательство «Белый Ветер». 2015.С.177-200.Kozlovskaya NL, Zakharova
EV, Korotchaeva YV. Glomerulonefrit pri systemnoy krasnoy volchanke v knige Natsionalnye
klinicheskie recomendatsii po lechenyu glomerulonefritov. Publisher “Belyj Veter”. 2015.P.177-200. (in Russian) - Fanouriakis A, Kostopoulou M, Cheema K et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant
Association (EULAR/ERAEDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713- 723. DOI: 10.1136/annrheumdis-2020-216924 - Козловская НЛ, Соловьев СК, Асеева ЕА и соавт. Обновленные рекомендации EULAR/ERA–EDTA 2019 г. по терапии волчаночного нефрита. Комментарии экспертов.
Часть I. Современная ревматология. 2020;14(4):7-15. Kozlovskaya NL, Solovyev SK, Aseeva E.A et al. The of lupus nephritis. Expert comments. Part I. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2020;14(4):7-15. (In Russ.) DOI: 10.14412/1996-7012-2020-4-7-15 - Jeong S, Yang D, Lee W et al. Diagnostic value of screening enzyme immunoassays compared to indirect immunofl uorescence for anti-nuclear antibodies in patients with systemic
rheumatic diseases: A systematic review and meta-analysis. Semin Arthritis Rheum. 2018;48(2):334-342. DOI: 10.1016/j.semarthrit. 2018.01.011 - Birmingham DJ, Irshaid F, Nagaraja HN et al. The complex nature of serum C3 and C4 as biomarkers of lupus renal fl are. Lupus. 2010;19(11):1272-1280. DOI: 10.1177/0961203310371154
- Yang XW, Tan Y, Yu F et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus Nephrol Dial Transplant. 2012;27(9):3552-3559. DOI: 10.1093/ndt/gfs179
- Stanley JH, Cornella R, Loevinger E et al. Sonography of systemic lupus nephritis. Am J Roentgenology. 1984;142(6):1165- 1168. DOI: 10.2214/ajr.142.6.1165.
- Longmaid HE 3rd, Rider E, Tymkiw J. Lupus nephritis. New sonographic fi ndings. J Ultrasound Med. 1987;6(2):75-79. DOI: 10.7863/jum.1987.6.2.75
- Thurman JM, Serkova NJ. Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. F1000Research. 2015;4:153. DOI: 10.12688/f1000research.6587.2
- Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part II: gastrointestinal, renal, and musculoskeletal manifestations. Clin Radiol. 2013;68(2):192-202. DOI: 10.1016/j. crad.2012.06.109.
- Conti F, Ceccarelli F, Gigante A et al. Ultrasonographic Patients with Lupus Nephritis: Correlation with Histologic Findings. Ultrasound in Med Biol. 2014;40(11):2573-2580. DOI: 10.1016/j.ultrasmedbio. 2014.06.016
- Tektonidou MG. Renal involvement in the antiphospholipid syndrome (APS) – APS nephropathy. Clin Rev Allergy Immunol. 2009;36(2-3):131-140. DOI: 10.1007/s12016-008-8112-z
- Lalani TA, Kanne JP, Hatfield GA, Chen P. Imaging
fi ndings in systemic lupus erythematosus. Radiographics.
2004;24(4):1069-1086. DOI: 10.1148/rg.244985082 - Goh YP, Naidoo P, Ngian GS. Imaging of systemic lupus erythematosus. Part I: CNS, cardiovascular, and thoracic manifestations. Clin Radiol. 2013;68(2):181-191. DOI: 10.1016/j. crad.2012.06.110
- van Vollenhoven RF, Mosca M, Bertsias G et al. Treat-totarget in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-967. DOI: 10.1136/annrheumdis-2013-205139
- Markowitz GS, D’Agati VD. The ISN/RPS 2003 classifi cation of lupus nephritis: An assessment at 3 years. Kidney Int. 2007;71(6):491-495. DOI: 10.1038/sj.ki.5002118
- Rijnink EC, Teng YKO, Kraaij T et al. Validation of the Systemic Lupus International Collaborating Clinics classifi cation criteria in a cohort of patients with full house glomerular deposits. Kidney Int. 2018;93(1):214-220. DOI: 10.1016/j.kint.2017.07.017
- Wang H, Ren YL, Chang J et al. A Systematic Review and Meta-analysis of Prevalence of Biopsy-Proven Lupus Nephritis. Arch Rheumatol. 2017;33(1):17-25. DOI: 10.5606/ArchRheumatol. 69. Fanouriakis A, Kostopoulou M, Alunno A et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736- 745. DOI: 10.1136/annrheumdis-2019-215089
- van Vollenhoven R, Voskuyl A, Bertsias G et al. A framework for remission in SLE: consensus fi ndings from a large international task force on defi nitions of remission in SLE (DORIS).
Ann Rheum Dis. 2017;76(3):554-561. DOI: 10.1136/annrheumdis- 2016-209519 - Houssiau FA. Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients. Arthritis Res Ther. 2012;14:202. DOI: 10.1186/ar3656
- Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P et al. Clinical effi cacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Disь 2010;69(1):20-28. DOI: 10.1136/ard.2008.101766
- Pakchotanon R, Gladman DD, Su J, Urowitz MB. More Consistent Antimalarial Intake in First 5 Years of Disease is Associated with Better Prognosis in Patients with Systemic Lupus Erythematous. J Rheumatol. 2018;45(1):90-94. DOI: 10.3899/ jrheum.170645
- Sisó A, Ramos-Casals M, Bové A et al. Previous antimalarial therapy in patients diagnosed with lupus nephritis: Infl uence on outcomes and survival. Lupus. 2008;17(4):281-288. DOI: 10.1177/0961203307086503
- Pons-Estel GJ, Alarcón GS, McGwin G Jr et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis 2009;61(6):830-839. DOI: 10.1002/art.24538
- Zavala-Miranda MF, Perez-Arias AA, Márquez-Macedo SE et al. Characteristics and outcomes of a Hispanic lupus nephritis cohort from Mexico. Rheumatology. 2023;62(3):1136– 1144. DOI: 10.1093/rheumatology/keac407
- Sciascia S, Mompean E, Radin M et al. Rate of adverse effects of medium- to high-dose glucocorticoid therapy in systemic lupus erythematosus: a systematic review of randomized control trials. Clin Drug Investig. 2017;37(6):519-524. DOI: 10.1007/ s40261-017-0518-z
- Bharati J, Rathi M. Comparison of two steroid regimen. Indian J Nephrol. 2019.;29(5):373-375. DOI: 10.4103/ijn. IJN_299_18
- Bandhan IH, Islam MN, Ahmad HI, Ahmedullah AK. Outcome of low-dose prednisolone use for the induction of remission in lupus nephritis patients. Int J Rheum Dis. 2022;25(2):121-130. DOI: 10.1111/1756-185X.14265
- Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I et al. Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening longterm disease control: an observational study. Arthritis Care Res. 2018;70(4):582-591. DOI: 10.1002/acr.23322
- Singh JA, Hossain A, Kotb A et al. Risk of serious infections with immunosuppressive drugs and glucocorticoids for lupus nephritis: a systematic review and network meta-analysis.
BMC Med. 2016;14(1):137-149. DOI: 10.1186/s12916-016- 0673-8 - Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C et al. Repeated pulses of methylprednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev. 2017;16(8):826-2. DOI: 10.1016/j.autrev.2017.05.017
- Bomback AS, Appel GB. Updates on the treatment of
lupus nephritis. J Am Soc Nephrol. 2010;21(12):2028-2035. DOI: 10.1681/ASN.2010050472 - Hu W, Chen Y, Wang S et al. Clinical–Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol. 2016;11(4):585-592. DOI: 10.2215/CJN.06720615
- Hu WX, Chen YH, Bao H et al. Glucocorticoid with or without additional immunosuppressant therapy for patients with lupus podocytopathy: a retrospective single-center study. Lupus.
2015;24(10):1067-1075. DOI: 10.1177/0961203315578766 - Bomback AS. Nonproliferative forms of lupus nephritis: an overview. Rheum Dis Clin North Am. 2018;44(4):561-569. DOI: 10.1016/j.rdc.2018.06.003
- Wang Y, Yu F, Song D et al. Podocyte involvement in lupus nephritis based on the 2003 ISN/RPS system: a large cohort study from a single centre. Rheumatology (Oxford). 2014;53(7):1235-1244. DOI: 10.1093/rheumatology/ket491
- Yu F, Haas M, Glassock R, Zhao MH. Redefi ning lupus nephritis: clinical implications of pathophysiologic subtypes. Nat Rev Nephrol. 2017;13(8):483-495. DOI: 10.1038/nrneph.2017.85 9. Houssiau FA, Vasconcelos C, D’Cruz D et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous
cyclophosphamide. Arthritis Rheum. 2002;46(8):2121-2131. DOI: 10.1002/art.10461 - Houssiau FA, Vasconcelos C, D’Cruz D et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing lowdose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-64. DOI: 10.1136/ard.2008.102533
- Rijnink EC, Teng YKO, Wilhelmus S et al. Clinical and histopathologic characteristics associated with renal outcomes in lupus nephritis. Clin J Am Soc Nephrol. 2017;12(5):734-743. DOI: 10.2215/CJN.10601016
- Henderson LK, Masson P, Craig JC et al. Induction and maintenance treatment of proliferative lupus nephritis: a metaanalysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74-87. DOI: 10.1053/j.ajkd.2012.08.041
- Tunnicliffe DJ, Palmer SC, Henderson L et al. Immunosuppressive treatment for proliferative lupus nephritis. Cochrane Database Syst Rev. 2018;6(6):CD002922. DOI: 10.1002/14651858. CD002922.pub4
- Furie R, Rovin BH, Houssiau F et al. Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis. N Engl J Med. 2020;383(12):1117-1128. DOI: 10.1056/NEJMoa2001180
- Collins CE, Cortes-Hernandez J, Garcia MA et al. Real- World Effectiveness of Belimumab in the Treatment of Systemic Lupus Erythematosus: Pooled Analysis of Multi-Country Data from the OBSErve Studies. Rheumatol Ther. 2020;7(4):949-965. DOI: 10.1007/s40744-020-00243-2
- Furie R, Rovin BH, Houssiau F et al. Safety and Effi - cacy of Belimumab in Patients with Lupus Nephritis: Open- Label Extension of BLISS-LN Study. Clin J Am Soc Nephrol. 2022;17(11):1620-1630. DOI: 10.2215/CJN.02520322
- Rovin BH, Furie R, Teng YKO et al. A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation
of kidney function in patients with lupus nephritis. Kidney Int. 2022;101(2):403-413. DOI: 10.1016/j.kint.2021.08.027 - Frangou E, Bruchfeld A, Fernandez-Juarez GM et al. EULAR 2023 recommendations for SLE treatment: synopsis for the management of lupus nephritis: the European Renal Association–Immunonephrology Working Group (ERA-IWG) perspective. Nephrol Dial Transplant. 2024;39(5):727-730. DOI: 10.1093/ndt/gfad230
- Appel GB, Contreras G, Dooley M.A et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-1012. DOI:
10.1681/ASN.2008101028 - Walsh M, Solomons N, Lisk L et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis with poor kidney function: a subgroup analysis of the Aspreva lupus management study. Am J Kidney Dis. 2013;61(5):710-715. Doi: 10.1053/j.ajkd.2012.11.042
Выпуск
Другие статьи выпуска
КЛИНИЧЕСКИЕ ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ KDIGO 2024 ПО ВЕДЕНИЮ ВОЛЧАНОЧНОГО НЕФРИТА (2024)
Авторы:
Гарабед Экноян
Эта статья опубликована как часть выпуска журнала, спонсируемая Инициативой по улучшению глобальных исходов заболеваний почек (Kidney Disease: Improving Global Outcomes/(KDIGO). Мнения и взгляды, высказанные в этой статье – это мнения и взгляды ее авторов, и они не обязательно отражают мнения или рекомендации Международного общества нефрологов (International Society of Nephrology) или издательства Elsevier. Дозировки, показания и методы использования продуктов, на которые ссылаются авторы статьи, могут отражать их клинический опыт или быть получены из медицинской литературы и других клинических источников. Вследствие различий между результатами, полученными in vitro и in vivo, и между лабораторными моделями на животных и клиническими данными, полученными у человека, данные in vitro и у животных не обязательно коррелируют с клиническими результатами.
Издательство
- Издательство
- РДО
- Регион
- Россия, Москва
- Почтовый адрес
- 123182, г Москва, р-н Щукино, ул Пехотная, д 3 стр 3
- Юр. адрес
- 123182, г Москва, р-н Щукино, ул Пехотная, д 3 стр 3
- ФИО
- Захарова Елена Викторовна (ПРЕДСЕДАТЕЛЬ)
- Сайт
- https://nephro.ru/